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Vacant spots for stem cells
Like cars circling city blocks on Saturday night, stem cells stand a good chance of finding a 
parking spot in bone marrow if they circulate long enough. Hematopoietic stem cells frequently 
leave their niches, freeing up space for other stem cells to enter, report Bhattacharya et al.
Their finding explains a paradox posed by bone marrow transplantations that replaced 
recipients’ blood supplies without radiation treatment. Radiation treatments are normally used in 
part to clear a recipient’s malfunctioning stem cells, thus freeing up limited stem cell space. And 
although studies suggest that stem cells exit their niches periodically, researchers have thought that 
the cells first underwent mitosis, leaving a replacement in their wake.
By labeling cells with BrdU, however, the team found that not all hematopoietic stem cells divide 
before they exit the bone marrow. And they appear to go away often, as one to five hematopoietic 
stem cells were found in the blood stream of mice at any particular time. The cells circulated for about 
five minutes—meaning that more than 1,000 stem cells enter circulation each day.
Steady stem cell egress could account for the authors’ finding that transplantation was enhanced 
when mice were given small numbers of donor stem cells repeatedly over seven days as compared 
with a single large dose.
Although hematopoietic stem cells appear to return to their niche, the extent to which this 
happens is unknown, as are the signals that drive the cells out or welcome them in. If the factors 
coordinating this process can be better understood, induced vacancies could provide an alternative 
to radiation treatments and their accompanying side effects. AM
HIV sticks to sperm
Sperm, and not just the fluid it bathes in, can transmit HIV to macrophages, T cells, and dendritic 
cells (DCs), report Ceballos and colleagues. By infecting DCs, which carry the virus and potently 
pass it to T cells, sperm may play a leading role in spreading HIV.
During sexual intercourse, HIV-infected men transmit HIV through their semen, which 
carries free-floating virus as well as HIV-infected leukocytes. Traces of HIV have been detected 
on sperm as well, but the role they play in viral transmission has been a matter of debate. After all, 
men with vasectomies can transmit HIV. Now, Ceballos et al. show that HIV attaches to the 
surface of sperm and that these HIV carriers pass on the virus to DCs and other HIV targets.
Sperm express molecules known to interact with HIV’s envelope, such as heparan sulfate and 
mannose receptors. The authors show that HIV relies on heparan sulfate to attach to sperm, but 
not mannose receptors as previously predicted.
Once attached, the virus was transmitted from sperm to DCs in culture. The DC receptors CD4 
and DC-SIGN were required for transmission, suggesting that DCs pick up the virus by binding to 
sperm rather than by ingesting them. DCs matured after interacting with the sperm, producing 
tolerance-promoting cytokines like interleukin-10. The authors speculate that this immune-
suppressing profile, versus an inflammatory profile, might also help the virus spread.
Sperm might reach DCs by passing through microabrasions in the vaginal or anal lining that 
often form during intercourse, suggest the authors. Or they might contact the finger-like 
projections of DCs that extend to the surface of mucosal linings. Furthermore, the team found 
that a slightly acidic pH, similar to the pH in the vagina after sex, promoted HIV–sperm binding 
and the subsequent rate of sperm-related DC infection. AM
After 12 days, many hematopoietic 
stem cells in circulation hadn’t 
incorporated BrdU, meaning that 
they didn’t divide before leaving 
the bone marrow.
Spermatozoa (arrows) transmit 
HIV when they attach to dendritic 
cells (red).
Mapping TB resistance
The first genetic resistance factor for tuberculosis (TB) infection is now reported by Cobat et al. 
The group has identified one locus that determines whether an individual will respond to the TB 
skin test and a second that controls the extent of that response. The results suggest that one major 
genetic locus controls innate resistance to the pathogen in humans.
Two-thirds of the global population is infected with Mycobacterium tuberculosis, the agent 
responsible for TB. Yet the disease only manifests in about 10% of infected individuals. To find 
genetic variants controlling susceptibility to infection, the authors studied 128 families in Cape 
Town, South Africa, where TB is highly endemic.
Although most subjects were likely to have been exposed to M. tuberculosis, about 40% did not 
show delayed type hypersensitivity (DTH) in a skin antigen test. This strong resistance mapped to a In This Issue | The Journal of Experimental Medicine  2579
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6-Mbp chromosome region, 11p14. This locus may unveil cellular mechanisms that might one day be 
manipulated to prevent TB—an important goal given the recent rise in drug-resistant strains.
The second locus, in the 2.9-Mbp 5p15 region, segregated with differing extents of positive DTH 
responses. These genetic factors might contribute to whether an infected individual keeps the bacterium 
dormant or develops the disease. The same chromosomal region is associated with susceptibility to 
sarcoidosis, an immune disorder of persistent inflammation that is often associated with TB.
A candidate 5p15 gene is a solute carrier (SLC) family member. A human SLC member called 
NRAMP1 is known to influence granuloma responses to mycobacteria, and loss of the mouse 
SLC6A3 protein reduces DTH response to ovalbumin. NL
Toxoplasma hosts ROP’d into STAT3 activation
A lone amino acid change determines success or failure for strains of Toxoplasma gondii, say 
Yamamoto et al. The group identifies a kinase mutation that thwarts one strain’s ability to activate 
Stat3 and halt the host immune response.
T. gondii comes in three chief flavors: types I, II, and III. Unfortunately for types II and III, 
their genetic differences severely cripple infectivity. The genetic changes in type II parasites 
disable T. gondii’s ability to down-regulate protective host cytokines by turning on the Stat3 
transcription factor. Exactly how the type I parasite activates Stat3 was unknown, but a 
polymorphism was recently mapped to a gene encoding a secretory organelle kinase called 
ROP16. And inserting type I ROP16 into type II parasites helped them activate Stat3.
Yamamoto et al. have now created a type I strain that lacks ROP16. Like normal type II 
parasites, the type I mutant failed to activate Stat3 and as a result induced host cytokines. Expression 
of ROP16 in mammalian cells, on the other hand, pumped up STAT3 activity by triggering its 
phosphorylation and nuclear translocation.
ROP16 kinase activity was necessary for Stat3 activation, and in vitro evidence suggested the 
phosphorylation may be direct, as ROP16 directly bound to and phosphorylated Stat3. The 
group found that a single leucine-to-serine substitution in type II ROP16 disabled Stat3 activation. 
The residue is not essential for kinase activity, but in silico modeling suggested the serine creates 
a misshapen active site. NL
FAK (green) and G help reseal 
endothelial adherens junctions (red) 
that are opened by G upon thrombin 
exposure.
A polymorphism in the Toxoplasma 
gondii (shown) ROP16 kinase prevents 
host activation of STAT3 and thereby 
cripples the infectivity of the type II 
strain of the parasite.
At junctions, G tears and G repairs
A team of G protein subunits have opposing agendas during thrombin-induced increases in lung 
vessel permeability, show Knezevic and colleagues. Once separated, G and G subunits act to 
open and close, respectively, cell–cell adhesions. The findings implicate the G pathway in 
deadly disorders causing persistently leaky vessels.
A transient opening of endothelial cell–cell adhesion allows immune cells to infiltrate tissue 
and fight infection and injury. Thrombin instigates this opening by cleaving the G-protein-
coupled PAR1 receptor. Upon subsequent G-protein dissociation, the G subunit initiates 
RhoA- and MLCK-mediated cell contraction, which pulls apart cell–cell adhesions called 
adherens junctions, thus creating leaky vessels.
The group’s research now shows that freed G works to undo G’s efforts. By blocking expression 
of the main endothelial G isoform, Knezevic et al. found that loss of G prevented the resealing 
of adherens junctions, which typically occurred two to three hours after their opening.
Interaction partners of G that are also known to regulate adherens junctions include Focal 
Adhesion Kinase (FAK) and the scaffolding protein RACK1. The group had previously shown 
that FAK suppresses the RhoA cell contraction pathway. They now show that G is required 
for FAK activation after thrombin exposure.
Without thrombin, G associated with RACK1 in endothelial cells. But with thrombin, the 
group saw, G left RACK1 and joined FAK and its kinase, Fyn. What controls the system’s 
timing, such that G undoes junctions well before G rezips them, is not yet clear.
Mice lacking Fyn were unable to turn on FAK and had problems resolving fluid leakage into 
their lungs upon PAR1 activation. This edema was lessened with the transduction of a version of 
FAK that mimics its phosphorylation. The findings identify a potential new therapy target for the 
treatment of acute respiratory distress syndrome (ARDS), which kills tens of thousands of patients 
in the US every year. NL
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